Project Grant R43AI147734

The National Institute of General Medical Sciences (NIGMS) awarded a $333,048 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to Imagen Bioworks Inc. in Houston, TX. The objective of this 1-year project is to develop a versatile 2-photon microscopy-based platform, dubbed "2P-Spotlight," that can isolate individual cells from 3D tissue samples after spatiotemporal profiling. This will address a critical limitation of current single-cell...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,274,742 to Northwestern University to develop a microfluidic cell sorting and culturing system for the rapid isolation and expansion of circulating tumor-reactive lymphocytes (CTRLs) from the blood of ovarian cancer patients. The project aims to engineer innovative microfluidic devices capable of isolating rare CTRLs directly from patient blood...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Detection and Diagnosis Research (CFDA 93.394), provides $554,653 to the Institute for Systems Biology (ISB) to develop and validate the "RareCyteFinder" toolkit. This label-free, genome-wide analysis platform aims to enable unbiased identification and comprehensive molecular profiling of rare disseminated tumor cells, including circulating tumor cells (CTCs) and isolated tumor...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $679,188 to The Regents of the University of California, San Francisco to develop liquid biopsy tools for detecting and profiling malignant effusions associated with metastatic breast cancer. The key objectives are to: 1) Validate an AI-assisted, morphology-based platform to isolate circulating tumor cells from malignant effusions; 2) Perform molecular characterization...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a novel molecular imaging approach to non-invasively track and identify genome-edited immune cells in vivo. The $497,870 award will fund the creation of engineered mammalian cells expressing bacterial metallophore transporters, which can selectively bind and be imaged using copper-64 radionuclide PET probes. This technology aims...

The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...

This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development and optimization of a novel single-cell multi-omic profiling method called SHARE-ME-SEQ. The $237,023 award will enable the Icahn School of Medicine at Mount Sinai to create a scalable and cost-effective technique to simultaneously capture gene expression, chromatin accessibility, and DNA methylation data at the single-cell level. The goal is to apply this method...

The National Cancer Institute (NCI) awarded a $734,980 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to Aperture Bio, Inc., a woman-owned small business located in Boston, MA. The goal of this 1-year project is to commercialize a platform for rapid, single-cell proteomic profiling to enable improved diagnostic and treatment outcomes for cancer patients. The funded work aims to develop a validated panel for profiling immune cells, which can be used on...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $671,072 to the University of Washington to develop a novel "picoliter thin-layer chromatography (PTLC)" device. This miniaturized lab-on-chip technology aims to improve the sensitivity and throughput of thin-layer chromatography, enabling single-cell analysis of lipid-modifying enzyme activity in cancer patient samples. The project will...